AMS BioteQ has achieved significant progress in the global wound dressing market by successfully obtaining U.S. FDA approval.

 AMS BioteQ has achieved significant progress in the global wound dressing market by successfully obtaining U.S. FDA approval. 

By ANUE

AMS BioteQ (TPE: 6864) announced on 11th Dec. last year that its innovative medical care product, "SIPSIPᵀᴹ Foam," the wound dressing made of its patented bioengineering technology ExtrOᵀᴹ, has successfully obtained the registration number issued by the U.S. FDA. The product is now fully equipped to enter the U.S. market. SIPSIPᵀᴹ Foam boasts outstanding anti-adhesive, high water absorption, and tissue regeneration capabilities, making it particularly suitable for wound care needs in the elderly and diabetic populations. This marks the first self-developed product from AMS BioteQ to receive FDA registration, setting up a significant milestone in product development and corporate mission. It also accelerates AMS BioteQ's global market expansion.

The Chairman of AMS BioteQ stated that SIPSIPᵀᴹ innovative hydrophilic dressing series is definitely a highlight of the company's innovative medical materials for now. In fact, it made its debut at the Medical Japan 2023 Tokyo in October last year and has garnered high attention from various biotech industries. With certifications from the U.S. FDA and Taiwan FDA, the company has been actively engaged with Japanese enterprise recently. They’re ambitiously planning to apply for relevant permits for medical equipment in Japan. In addition to aim at the Japanese healthcare market, AMS BioteQ has recently received attention from international medical equipment companies, especially in MENA and ASEAN regions, creating more probabilities and potential for the overseas wound dressing market.

R&D Supervisor, Mr. Ying-Ting Yeh stated that SIPSIPᵀᴹ Foam is the perfect pioneer among these series. With the exclusive ExtrO patented bioengineering technology, AMS BioteQ is eager to develop a variety of innovative hydrophilic dressings under SIPSIPᵀᴹ line, including SIPSIPᵀᴹ Foam, SIPSIPᵀᴹ Pro and SIPSIPᵀᴹ Complex. These dressings share some remarkable features in common, such as wound healing technology, unique physical structure, hypoallergenic properties, high water absorption, etc. The products not only show fantastic biocompatibility and high hydrophilicity but also have been proven to promote wound healing and functional tissue regeneration through animal experiments (mouse model).

AMS BioteQ is stepping into its sixth year, has successfully established the dual-track approach in drug discovery and wound dressings. This provides more diverse range of options for medical professionals and patients. In the future, the company will continue to invest in the development of different indications, expanding its international market and technological influence, with the aspiration to become one of the leading brands in global medical market.